PTEN and neoplasm: However, there was a trend towards OS benefit with Xe1000 + En160 versus En160 in patients with tumours with PTEN H-score >220 (median OS 19.4 vs 12.7 months; HR 0.66 [95% CI 0.24–1.81]; Fig. 4b).